Charles Schwab
CBPO

Charles Schwab’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Charles Schwab’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,796
Closed -$3.41M – 3639
2021
Q1 		$3.41M Buy
28,796
+773
+3% +$91.4K ﹤0.01% 2480
2020
Q4 		$3.31M Buy
28,023
+870
+3% +$101K ﹤0.01% 2418
2020
Q3 		$3.02M Sell
27,153
-852
-3% -$91.5K ﹤0.01% 2325
2020
Q2 		$2.86M Sell
28,005
-3,877
-12% -$415K ﹤0.01% 2290
2020
Q1 		$3.44M Sell
31,882
-1,812
-5% -$208K ﹤0.01% 2022
2019
Q4 		$3.92M Buy
33,694
+814
+2% +$94.3K ﹤0.01% 2151
2019
Q3 		$3.76M Buy
+32,880
New +$3.27M ﹤0.01% 2119

Charles Schwab's CBPO Position: Q2 2021 in Review

Charles Schwab sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 28,796 shares — an estimated $3.41M sold.

Charles Schwab first reported a position in CBPO in Q3 2019 and held it in 7 quarters. The position peaked at $3.92M in Q4 2019. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

  • Charles Schwab reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
  • Charles Schwab sold 28,796 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $3.41M.
  • Charles Schwab first reported a position in China Biologic Products Holdings, Inc. in Q3 2019 and held it in 7 quarters.
  • Charles Schwab's China Biologic Products Holdings, Inc. position peaked at $3.92M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.